Shattuck Labs, Inc. Proceeds from Stock Plans
Shattuck Labs, Inc. (STTK) reported Proceeds from Stock Plans of $100.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2022-11-09
- Shattuck Labs, Inc. proceeds from stock plans for the quarter ending 2022-09-30 was $100.00K, a 0.00% change year-over-year.
- Shattuck Labs, Inc. proceeds from stock plans for the quarter ending 2022-06-30 was $100.00K.
- Shattuck Labs, Inc. proceeds from stock plans for the quarter ending 2021-12-31 was $0.00.
- Shattuck Labs, Inc. proceeds from stock plans for the quarter ending 2021-09-30 was $100.00K.
- Shattuck Labs, Inc. proceeds from stock plans for fiscal 2021 was $100.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-09 | $200.00K derived: sum of 2 quarters · filed 2022-11-09 | $100.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-11 | $100.00K 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $100.00K derived: sum of 2 quarters · filed 2022-11-09 | $100.00K 10-K · filed 2022-03-15 | |
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-09 | $100.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |